Share on Facebook
Share on Twitter
Share on LinkedIn
Share by Email
Print
Cyfendus Generic Name & Formulations
Legal Class
General Description
Pharmacological Class
How Supplied
Multiple-dose vial (5mL)—1
Manufacturer
Generic Availability
NO
Mechanism of Action
Cyfendus induces antibodies against protective antigen protein that may contribute to protection by neutralizing the activities of the cytotoxic lethal toxin and edema toxin of Bacillus anthracis.
Cyfendus Indications
Indications
Post-exposure prophylaxis of disease after suspected or confirmed exposure to Bacillus anthracis, when given with recommended antibacterial drugs.
Cyfendus Dosage and Administration
Adult
For IM inj only. Each dose is 0.5mL. 18–65yrs: give as a 2-dose series at 0 and 2 weeks post-exposure in combination with antibacterial therapy.
Children
<18yrs: not established.
Cyfendus Contraindications
Contraindications
Severe allergic reaction after a previous Cyfendus or BioThrax dose.
Cyfendus Boxed Warnings
Not Applicable
Cyfendus Warnings/Precautions
Warnings/Precautions
Have medical treatment and supervision available to manage anaphylactic reactions. Immunocompromised. Elderly (>65yrs): not established. Pregnancy. Nursing mothers.
Cyfendus Pharmacokinetics
See Literature
Cyfendus Interactions
Not Applicable
Cyfendus Adverse Reactions
Adverse Reactions
Inj-site reactions (tenderness, pain, arm motion limitation, warmth, induration, itching, swelling, erythema/redness), muscle aches, tiredness, headache.
Cyfendus Clinical Trials
See Literature
Cyfendus Note
Not Applicable
Cyfendus Patient Counseling
See Literature
